CurrentBlue Cross Blue Shield - OklahomaPolicy CPCPLAB055

Parathyroid Hormone, Phosphorous, Calcium and Magnesium Testing

Defines Blue Cross Blue Shield of Oklahoma reimbursement criteria and coding guidance for laboratory testing of parathyroid hormone (PTH), phosphorus, calcium and magnesium for covered members and participating providers.

Policy Summary

PayerBlue Cross Blue Shield - Oklahoma

PolicyParathyroid Hormone, Phosphorous, Calcium and Magnesium Testing

Policy CodePolicy CPCPLAB055

Change TypeLiterature review — reimbursement unchanged

Effective DateApr 29, 2024

Next Review Date

Key ActionProviders must submit accurate documentation and use valid code combinations when submitting claims; additional documentation may be requested.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

7procedure codes listed (non-exhaustive)

5reimbursable PTH scenarios enumerated

4tests non-reimbursable for wellness/general exam

1policy version listed

Coverage and Medical Necessity

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Reimbursement criteria

Situations when serum intact PTH and related tests may or may not be reimbursable:

ALL of the following

ANY of the following
- To assess for possible hyperparathyroidism in individuals with hypercalcemia.
- To assess post-operative results of parathyroid surgery.
- As part of annual testing of an individual previously diagnosed with hyperparathyroidism.
- As part of an assessment of chronic kidney disease (CKD).
- As part of an assessment of osteoporosis.
- As part of a diagnosis and/or assessment of cancer or cancer therapy.

ALL of the following

ANY of the following
- Initial assessment and diagnosis of the disorders (see Note 1).
- To monitor disease and/or therapy.

ALL of the following

Serum intact PTH testing to screen for asymptomatic hyperparathyroidism is not reimbursable.
When individuals present for a wellness or general exam without abnormal findings, the following tests are not reimbursable: serum, blood, or fecal magnesium; serum or urine phosphorus/phosphate; serum total calcium, serum ionized calcium, or urine calcium; and serum parathyroid hormone testing.
Testing serum for truncated parathyroid hormone metabolites (e.g., amino-terminal and carboxy-terminal fragments) is not reimbursable.

ALL of the following

NOTE 1: Conditions referenced include hypoparathyroidism, pseudohypoparathyroidism, and related disorders (Mantovani et al., 2018).

Coverage notes and missing criteria

Context, references, and update history for this policy segment; specific additional coverage or billing rules are not present in the provided excerpt.

ALL of the following

NICE (2023): Suspected Cancer: Recognition and Referral.
American Thyroid Association statement on postoperative hypoparathyroidism (Orloff et al., 2018).
Selected literature on calcium, phosphate, magnesium, and PTH measurement and clinical use (e.g., Shaker & Deftos; Sturgeon et al.; Sri-Ganeshan et al.).

ALL of the following

The provided excerpt does not include explicit additional coverage criteria, billing modifiers, or denial rules; reviewers should merge this Part with other policy parts for complete criteria and operational billing instructions.

Procedure Codes and Coding Guidance

Example procedure codes related to calcium, phosphorus, magnesium and PTH testingCPT

82310
82330
82340
83735
83970
84100
84105

No explicit CPT/HCPCS/ICD-10 codes in this document segmentmixed

No codes listed

Numeric Thresholds Absent

Numeric test thresholdsNo numeric laboratory test thresholds or numeric cutpoints are provided in the policy excerpt; reviewers should not rely on this document for numeric decision limits.

Action for providers/labsUse laboratory reference ranges and clinical guidelines for numeric thresholds; submit supporting documentation when required by payer review.

Policy notePolicy text explicitly notes absence of numeric thresholds in the provided document segment.

Documentation, Claims and Provider Responsibilities

Documentation Required

Documentation and claim submission expectations

Providers must submit accurate documentation of services performed and submit claims using valid code combinations from HIPAA‑approved code sets. Claims must be coded according to industry standard coding guidelines (for example, Uniform Billing Editor, AMA CPT, HCPCS, ICD‑10 CM/PCS, NDCs, DRG guidelines, CMS NCCI edits) and are subject to code edit protocols and claim review; upon request providers should submit additional documentation.

Use valid code combinations from HIPAA‑approved code sets.
Code claims per industry standard guidelines (CPT, HCPCS, ICD‑10, CMS NCCI, etc.).
Claims are subject to code edit protocols and may require submission of additional documentation upon request.

Billing Rule

Reimbursement update history

Reimbursement information in this policy remained unchanged as of the 04/29/2024 update; the document was updated with a literature review and references were revised.

04/29/2024 — Document updated with literature review; reimbursement information unchanged; references revised.
Prior update 06/15/2023 revised reimbursement information for clarity.

Definitions and Supporting References

Specified Hypoparathyroid‑Related Disorders

HypoparathyroidismListed as a reimbursable indication for serum intact PTH testing (initial assessment/diagnosis and monitoring).

Pseudohypoparathyroidism Type 1A (PHP1A)Included as a related disorder due to maternal GNAS loss-of-function mutation; testing may be reimbursable.

Pseudohypoparathyroidism Type 1B (PHP1B)Included as a related disorder due to GNAS methylation defect; testing may be reimbursable.

Pseudopseudohypoparathyroidism (PPHP)Listed as a related disorder due to paternal GNAS loss-of-function mutation; testing may be reimbursable.

Progressive Osseous Heteroplasia (POH)Listed as a related disorder due to paternal GNAS loss-of-function mutation; testing may be reimbursable.

Acrodysostosis (ACRDYS1 and ACRDYS2)Both acrodysostosis types (PRKAR1A and PDE4D mutations) are listed as related disorders for which testing may be reimbursable.

Clinical References and Context

NICE Suspected Cancer guidance (2023)Cited among references supporting context for diagnostic assessment where PTH/mineral testing may be relevant.

Endotext: Calcium and Phosphate Homeostasis (Shaker & Deftos, 2023)Referenced as clinical background on calcium/phosphate homeostasis and PTH physiology.

IFCC perspective on PTH measurement (Sturgeon et al., 2017)Cited for priorities and methods related to accurate PTH assay measurement.

Selected research on PTH and minerals (Wojda & Donahue; Workinger et al.)Additional cited literature on PTH for bone regeneration and challenges in magnesium status assessment.

Policy Summary

PayerBlue Cross Blue Shield - Oklahoma

PolicyParathyroid Hormone, Phosphorous, Calcium and Magnesium Testing

Policy CodePolicy CPCPLAB055

Change TypeLiterature review — reimbursement unchanged

Effective DateApr 29, 2024

Next Review Date

Key ActionProviders must submit accurate documentation and use valid code combinations when submitting claims; additional documentation may be requested.

SourceLink

On This Page